Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.9% – What’s Next?

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) traded down 3.9% during mid-day trading on Monday . The company traded as low as $1.40 and last traded at $1.49. 9,347,751 shares were traded during trading, an increase of 5,373% from the average session volume of 170,796 shares. The stock had previously closed at $1.55.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, February 18th.

Citius Pharmaceuticals Stock Performance

The firm’s 50-day simple moving average is $2.08 and its 200-day simple moving average is $5.22.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). On average, equities research analysts anticipate that Citius Pharmaceuticals, Inc. will post -4.5 EPS for the current year.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CTXR. Tower Research Capital LLC TRC boosted its holdings in Citius Pharmaceuticals by 103.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after purchasing an additional 4,168 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after acquiring an additional 7,083 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in Citius Pharmaceuticals during the 4th quarter valued at approximately $51,000. Chelsea Counsel Co. increased its holdings in Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Miller Investment Management LP boosted its stake in Citius Pharmaceuticals by 99.3% during the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the last quarter. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.